TOSITUMOMAB 131I
drugOn this page
Also known as BexxarTositumomab/iodine (131i) tositumomab
Summary
Tositumomab 131I (CHEMBL3833304) is a phase-3 clinical-stage antibody (ATC V10XA53); indicated across 15 conditions including neoplasm of mature b-cells and lymphoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- ATC class: V10XA53
- Indications: 15 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3833304 |
| Name | TOSITUMOMAB 131I |
| Type | Antibody |
| Max phase | 3 |
| ATC | V10XA53 |
Also known as: Bexxar, Tositumomab 131i, Tositumomab/iodine (131i) tositumomab, TOSITUMOMAB 131I
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
15 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm of mature B-cells | 3 | MONDO:0004949 | EFO:0000096 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| non-Hodgkin lymphoma | 3 | MONDO:0018908 | EFO:0005952 |
| follicular lymphoma | 3 | MONDO:0018906 | MONDO:0018906 |
| B-cell chronic lymphocytic leukemia | 2 | MONDO:0004948 | EFO:0000095 |
| Burkitt lymphoma | 2 | MONDO:0007243 | EFO:0000309 |
| diffuse large B-cell lymphoma | 2 | MONDO:0018905 | EFO:0000403 |
| plasma cell myeloma | 2 | MONDO:0009693 | EFO:0001378 |
| anaplastic large cell lymphoma | 2 | MONDO:0020325 | EFO:0003032 |
| Waldenstrom macroglobulinemia | 2 | MONDO:0100280 | EFO:0009441 |
| mantle cell lymphoma | 2 | MONDO:0018876 | EFO:1001469 |
| MALT lymphoma | 2 | MONDO:0007650 | EFO:0000191 |
| lymphoid leukemia | 2 | MONDO:0005402 | EFO:0004289 |
| Hodgkins lymphoma | 1 | MONDO:0004952 | EFO:0000183 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00490009 | PHASE2 | COMPLETED | Phase 2 Study of Bexxar in Relapsed/Refractory DLCL |
| NCT00490490 | PHASE2 | TERMINATED | Study of Bexxar |
| NCT01389076 | PHASE2 | TERMINATED | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma |
| NCT00434629 | PHASE1 | COMPLETED | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).